U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H45Cl2N2O2
Molecular Weight 620.671
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of NOLPITANTIUM

SMILES

CC(C)OC1=CC(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)C5=CC=CC=C5)(C2)C6=CC=C(Cl)C(Cl)=C6)=CC=C1

InChI

InChIKey=RPDFDSQFBCJTDY-GAQXSTBRSA-N
InChI=1S/C37H45Cl2N2O2/c1-28(2)43-32-11-6-8-29(24-32)25-35(42)40-19-7-14-37(27-40,31-12-13-33(38)34(39)26-31)18-23-41-20-15-36(16-21-41,17-22-41)30-9-4-3-5-10-30/h3-6,8-13,24,26,28H,7,14-23,25,27H2,1-2H3/q+1/t36?,37-,41?/m1/s1

HIDE SMILES / InChI

Molecular Formula C37H45Cl2N2O2
Molecular Weight 620.671
Charge 1
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: the description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9824398 | https://www.ncbi.nlm.nih.gov/pubmed/9873386 | https://www.ncbi.nlm.nih.gov/pubmed/9243595 | https://www.ncbi.nlm.nih.gov/pubmed/20497542

Nolpitantium (SR-140333) is a highly selective nonpeptide antagonist of neurokinin-1 (NK1) receptor. Nolpitantium potently, selectively and competitively inhibited substance P binding to NK1 receptors from various animal species, including humans. In vitro, it was a potent antagonist in functional assays for NK1 receptors such as [Sar9, Met(O2)11]substance P-induced endothelium-dependent relaxation of rabbit pulmonary artery and contraction of guinea-pig ileum. Up to 1 mkM, Nolpitantium had no effect in bioassays for NK2 and NK3 receptors. The antagonism exerted by Nolpitantium toward NK1 receptors was apparently non-competitive, with pD2' values between 9.65 and 10.16 in the different assays. Nolpitantium also blocked in vitro [Sar9, Met(O2)11]substance P-induced release of acetylcholine from rat striatum. In vivo, Nolpitantium exerted highly potent antagonism toward [Sar9, Met(O2)11]substance P-induced hypotension in dogs, bronchoconstriction in guinea-pig) and plasma extravasation in rats. Nolpitantium was found to be effective in the modulation of the inflammatory response and airway remodeling in mice. Nolpitantium is reported to cause antagonism of the SP-induced relaxations of human isolated intralobar pulmonary arterial rings. Nolpitantium also blocked the activation of rat thalamic neurons after nociceptive stimulation. Nolpitantium has been shown to reduce the severity of inflammation in trinitrobenzene sulfonic acid-induced colitis in the rat colon. Nolpitantium inhibited mustard oil-induced plasma protein extravasations in the dorsal skin of the rat hind paw. Nolpitantium had been in some phase II clinical trials but further studies were discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.019 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
1996 Aug 23
Ava[L-Pro9,N-MeLeu10] substance P(7-11) (GR 73632) and Sar9, Met(O2)11 increase distention-induced peristalsis through activation of neurokinin-1 receptors on smooth muscle and interstitial cells of cajal.
2006 Apr
Expression and function of human hemokinin-1 in human and guinea pig airways.
2010 Oct 7
Patents

Sample Use Guides

Single daily doses of 600 mg SR140333B or 1800 mg of SR140333B for eight weeks.
Route of Administration: Oral
The human breast cancer cell line T47D was used for activity evaluation. Nolpitantium were dissolved in culture medium respectively to obtain experimental concentration (ranging from 10^-9M to 10^-5M). Cell proliferation was assessed using MTT assay. Cells were cultured in 96-well plates and the cell numbers were quantified using a coulter counter (Coulter Electronics, Inc., Hialeah, FL). Each well contained 2x 10^4cells in a total volume of 200 μL. The plate included blank wells (0 cells/mL), control wells (2 x10^4cells/0.2 Ml, untreated group), control wells with DMSO (no cells), control wells treated with SR140333 (Nolpitantium) (10^-9M-10^-5M), control wells treated with SMSP (10^-10M-10^-6M) and control wells treated with SMSP (most effective concentration) combined with different concentrations of SR140333 (10^-9M-10^-5M). Drugs were added on day 3 (at exponential phase) and the assay was performed after 24 hours. For the proliferation assay, 20 μL MTT was added to each well. After 4 hours at 37°C supernatant was removed and 100 μL DMSO was added to each well. The optical density (OD) was detected in the microplate reader at 570 nm wavelength
Substance Class Chemical
Created
by admin
on Sat Dec 16 03:03:59 GMT 2023
Edited
by admin
on Sat Dec 16 03:03:59 GMT 2023
Record UNII
NR72W2V70N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NOLPITANTIUM
Common Name English
NOLPITANTIUM ION
Common Name English
SR-140333
Code English
NOLPITANTIUM CATION
Common Name English
1-AZONIABICYCLO(2.2.2)OCTANE, 1-(2-((3S)-3-(3,4-DICHLOROPHENYL)-1-(2-(3-(1-METHYLETHOXY)PHENYL)ACETYL)-3-PIPERIDINYL)ETHYL)-4-PHENYL-
Systematic Name English
Code System Code Type Description
FDA UNII
NR72W2V70N
Created by admin on Sat Dec 16 03:04:00 GMT 2023 , Edited by admin on Sat Dec 16 03:04:00 GMT 2023
PRIMARY
EPA CompTox
DTXSID10165896
Created by admin on Sat Dec 16 03:04:00 GMT 2023 , Edited by admin on Sat Dec 16 03:04:00 GMT 2023
PRIMARY
PUBCHEM
108167
Created by admin on Sat Dec 16 03:04:00 GMT 2023 , Edited by admin on Sat Dec 16 03:04:00 GMT 2023
PRIMARY
CAS
155418-05-6
Created by admin on Sat Dec 16 03:04:00 GMT 2023 , Edited by admin on Sat Dec 16 03:04:00 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY